Pharmaceutical Giant Richter to Develop Anti-Obesity Agent [Video]

Richter’s current top drug Vraylar was sold last year for a total of EUR 3 billion and treated 1.3 million patients, the CEO of Richter announced at a press conference on Friday. The company’s development success story also continues with an anti-obesity agent in its most advanced phase, reports Magyar Nemzet.

The cariprazine-based antipsychotic Vraylar (adjunctive therapy to antidepressants for the treatment of major depressive disorder in adults) has made the list of the top 100 drugs, emphasized Gábor Orbán, CEO of Richter Gedeon. The original antipsychotic drug is available in pharmacies in Hungary and has become a blockbuster product in the U.S. The fact that a Hungarian drug candidate, discovered in Hungary and developed with Hungarian financial and technical support, has been granted FDA and EU registrations and is now available in 64 countries, is a unique achievement.

The CEO outlined the aim of the Richter …